Recent clinical trials showed transient hypoglycemia in patients with Pompe disease shortly after intravenous injection of recombinant IGF2.GAA at 10–20 mg/kg, but not at 5 mg/kg.73 Here, IGF2 is linked to glycogen storage disease II.